Galapagos discovers novel candidate drug to treat breast cancer

Galapagos discovers novel candidate drug to treat breast cancer  MECHELEN, BELGIUM -- (Marketwired) -- 04/22/13 --    * GLPG1790 has high efficacy against triple-negative breast cancer  * Innovative, targeted approach  * Galapagos plans to initiate clinical trials within one year  Galapagos NV (EURONEXT BRUSSELS: GLPG) announced today that  it developed  GLPG1790, a  novel candidate  drug to  treat breast cancer. GLPG1790 has shown high activity against breast tumors that are triple- negative, for  which the  absence of  estrogen (ER),  progesterone (PR)  or HER2 receptors affects  the prognosis  for recovery,  and no  targeted therapeutic options are currently available.  Breast cancer is a disease in which tumor cells form in the breast tissue; it is one of the most common types of cancer in women.  There are many different types of  breast  cancer,  and  as  a  result,  there are many options for treatment. Targeted  drug treatments such as Herceptin(R) and Avastin(R)[1] attack specific types  of breast cancer cells.  Decisions about the best possible treatment with targeted  drugs are  based on  tests for  the presence  of ER,  PR and HER2[2]. Triple-negative  breast  cancer  (tumor  cells  that  have  no  ER, PR and HER2) accounts  for one-fifth of breast cancers,  and it usually affects young women. There  are no targeted drugs available  for patients with triple-negative breast cancer.  Candidate  drug GLPG1790 is a  selective and potent inhibitor  of a novel breast cancer target; the candidate drug has proven to be highly active against triple-negative  breast cancer  in a  mouse xenograft  model where it completely blocks tumor  growth.  GLPG1790 has good  drug-like properties, and safety/tolerability studies  with  the  candidate  drug  look  favorable.   Galapagos  will initiate preclinical  studies with GLPG1790,  and expects to  initiate the first clinical trials  in humans within one  year.  This novel program  is fully proprietary to Galapagos.  "GLPG1790 is the result of a multi-year research program on a novel mechanism of action  discovered with our target discovery  platform," says Dr Piet Wigerinck, Galapagos  CSO. "We  are pleased  to have  developed a targeted approach towards triple-negativ e  breast cancer.   Targeted approaches in oncology typically show good efficacy and less toxicity than chemotherapy."  About Galapagos  Galapagos  (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is specialized in novel modes-of-action, with  a large  pipeline of  four clinical,  seven pre-clinical, and 30 discovery small-molecule   and   antibody   programs  in  cystic  fibrosis, inflammation, antibiotics, metabolic disease, and other indications. GLPG0634  is an orally-available, selective inhibitor  of JAK1 for the treatment of  rheumatoid arthritis and  potentially other inflammatory  diseases, about to enter  Phase  2b studies.   AbbVie  and  Galapagos  signed  a  worldwide license agreement  whereby  AbbVie  will  be  responsible  for  further development and commercialization   after   Phase  2b.  Galapagos  has  another  selective JAK1 inhibitor  in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in- licensed  by GlaxoSmithKline  in 2012).  GLPG0187  is a  novel integrin receptor antagonist currently in a Phase 1b patient study in metastasis.  GLPG0974 is the first  inhibitor of FFA2  to be evaluated  clinically for the  treatment of IBD; this program will start a Proof of Concept Phase 2 study this quarter. The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and Fidelta,  has over 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.  Further information at:  This   release   may  contain  forward-looking  statements,  including, without limitation,   statements   containing   the   words  "believes," "anticipates," "expects,"  "intends,"  "plans,"  "seeks,"  "estimates," "may," "will," "could," "stands  to," and  "continues," as  well as  similar expressions.  Such forward-looking  statements may involve known and unknown risks, uncertainties and other factors  which might cause the  actual results, financial condition, performance or  achievements of Galapagos,  or industry results,  to be materially different from  any  historic  or  future  results,  financial  conditions, performance or achievements  expressed  or  implied  by  such forward-looking statements. Given these  uncertainties, the reader is  advised not to place  any undue reliance on such  forward-looking statements. These forward-looking statements speak only as of  the date of publication of  this document. Galapagos expressly disclaims any obligation  to update  any such  forward-looking statements  in this document to reflect  any change  in its  expectations with  regard thereto  or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.  --------------------------------------------------------------------------- -----  [1]Herceptin(R) and Avastin(R) are registered trademarks of Roche for trastuzumab and bevacizumab, respectively  [2]Human epidermal growth factor type 2 receptor  This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:  (i) the releases contained herein are protected by copyright and     other applicable laws; and  (ii) they are solely responsible for the content, accuracy and      originality of the information contained therein.  Source: Galapagos NV via Thomson Reuters ONE  [HUG#1694682]  CONTACT  Galapagos NV Dr Piet Wigerinck Chief Scientific Officer Tel. +32 477 627103  Elizabeth Goodwin Director Investor Relations Tel: +31 6 2291 6240    
Press spacebar to pause and continue. Press esc to stop.